Drugs / rhPDGF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04954664 | Aug 2021 → Dec 2026 expected | bone resorption disease | University of Alabama at Birmingham | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhPDGF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04954664 ↗ |
| Known as | Recombinant Human Platelet-Derived Growth Factor | “a growth factor called Recombinant Human Platelet-Derived Growth Factor (rhPDGF)” NCT04954664 ↗ |
| Modality | Protein / enzyme biologic | “a growth factor called Recombinant Human Platelet-Derived Growth Factor (rhPDGF)” NCT04954664 ↗ |